Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its BoardAccesswire • 04/10/24
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.Barrons • 04/09/24
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid TumorsBusiness Wire • 04/06/24
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumorsBusiness Wire • 04/06/24
AstraZeneca cancer trial readout underlines immuno opportunity, suggests brokerProactive Investors • 04/05/24
AstraZeneca reports 'significant' patient improvement in latest Imfinzi cancer trialProactive Investors • 04/05/24
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerBusiness Wire • 04/02/24